Nicolas Folschweiller

Head Clinical Development Leads Vaccines

Biogen (Switzerland)

Switzerland

Research Interests

Explore related searches

Professors in Switzerland Professors in Immunology Immunology professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Nicolas Folschweiller serves as the Head of Clinical Development Leads for Vaccines at Takeda in Switzerland. His research primarily focuses on vaccine efficacy and safety, with recent articles addressing topics such as the tetravalent dengue vaccine (TAK-003) and the immunogenicity of HPV vaccines. Dr. Folschweiller is actively involved in clinical trials that assess the long-term effects of vaccines in various populations, including both children and older adults.

Articles (8)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2020

Year:

2020

Collaborators (1)

matti lehtinen

Karolinska University Hospital

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nicolas Folschweiller

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial

Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue

Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials

Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials

Collaborators (1)

matti lehtinen

Make your next move.